Stratasys Expands Availability of RadioMatrix™ Radiopaque Material to the United States

Key Terms

radiopaque medical

Materials or substances that block X-rays or other medical imaging beams, so they appear light or white on scans; think of them like a rock in a flashlight beam that casts a clear shadow. Investors care because radiopaque properties are critical for medical devices, implants, and contrast agents to be safely placed, monitored, and regulated, affecting product usability, approval, and market value.

radiopacity medical

Radiopacity is the property of a material that makes it visible on X-ray or other medical imaging, so devices or implants show up clearly on scans. For investors, radiopacity affects a product’s safety, ease of use in procedures, regulatory approval and clinical adoption—similar to how a bright marker on a map helps a driver navigate—so stronger visibility can influence sales, liability risk and market competitiveness.

computed tomography (CT) medical

Computed tomography (CT) is a medical imaging technique that uses X-ray technology to create detailed cross-sectional pictures of the inside of the body, similar to taking multiple slices of a loaf of bread to see its internal structure. For investors, understanding CT is important because it represents advanced technology that can improve diagnostics and healthcare efficiency, potentially influencing the performance of companies involved in medical imaging and health services.

Hounsfield units (HU) medical

A Hounsfield Unit (HU) is a number assigned to each pixel in a CT scan that measures how much X‑rays are absorbed by tissue, using water as a zero point and air as a very low reference. For investors, HU values turn images into objective, comparable data used to identify disease, track treatment effects, and validate diagnostic devices or software—think of HU like a grayscale brightness scale that reveals what a body part is made of, which affects regulatory approval, reimbursement and product marketability.

angiography medical

Angiography is a medical imaging procedure that maps blood vessels by injecting a visible dye and taking X‑ray, CT or MRI pictures to reveal narrowing, blockages or leaks. For investors, it matters because demand for angiography drives sales of imaging machines, contrast agents, catheters and devices used in minimally invasive treatments, and the test’s findings influence patient care decisions and overall healthcare spending—like using a plumbing camera to find and fix a blocked pipe.

First-ever radiopaque 3D printing material now fully available to U.S. healthcare providers

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)-- Stratasys Ltd. (NASDAQ: SSYS) today announced full commercial availability of its RadioMatrix™ radiopaque 3D printing material in the United States. This milestone follows initial limited deployments and marks the first time healthcare providers, device manufacturers, and research institutions across the U.S. can broadly access and utilize the material for advanced medical imaging and training applications.

Stratasys Expands Availability of RadioMatrix™ Radiopaque Material to the United States.

RadioMatrix is the first and only 3D printing material that enables precise control of radiopacity - allowing users to produce patient-specific models with repeatable, consistent, and fully tunable visibility on X-ray based imaging. Stratasys developed RadioMatrix to support a new era of medical imaging. Its unmatched fidelity for computed tomography (CT) phantoms was later underscored by research conducted with Siemens Healthineers, which validated RadioMatrix’s capabilities and accuracy for accelerating innovation in device testing, calibration, and education.

UK-based work with partners such as CPI and Beaumont Hospital is already demonstrating the impact of radiopaque 3D-printed models in practice, with radio-realistic cerebral angiography phantoms being used to improve the fidelity of imaging-based training and create more controlled, repeatable environments for research.

Early research from the Stratasys–Siemens Healthineers collaboration shows that 3D printed RadioMatrix™ phantoms can closely replicate real human tissue in CT imaging, with deviations reported as low as single Hounsfield units (HU) in critical areas such as grey matter and veins. By combining Stratasys’ Digital Anatomy™ 3D printing technology and radiopaque materials with advanced imaging algorithms, the partners are demonstrating anatomically realistic, radio-accurate phantoms that preserve fine anatomical details and pathological variations while offering a more consistent, ethical alternative to cadavers. These models are expected to improve how radiologists validate and optimize CT protocols and accelerate the development of new imaging algorithms for more precise diagnosis and treatment planning.

“Providing full availability of RadioMatrix in the U.S. is a major step in providing cutting-edge imaging education and training,” said Erez Ben Zvi, Vice President, Healthcare, Stratasys. “By giving radiologists and device manufacturers the ability to print ultra-realistic, customized radiographically accurate models, we’re helping replace traditional phantom solutions and reliance on cadavers with customizable, repeatable, and scalable alternatives.”

For more information or to request a benchmark model, contact a Stratasys representative or visit http://www.stratasys.com/healthcare.

About Stratasys

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, X/Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including Stratasys’ websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251201741020/en/

Media and Investor contacts:

Stratasys Corporate, North America & EMEA

Chris Reese

chris.reese@stratasys.com

+1 651 357 0877

Stratasys Corporate, Israel & EMEA

Erik Snider

Erik.Snider@stratasys.com

+972 74 745 6053

Investor Relations

Yonah Lloyd

Yonah.Lloyd@stratasys.com

+972 74 745 4919

Source: Stratasys Ltd.